VIB INKS QBASE+ GROUP LICENSING AGREEMENT WITH BIOGAZELLE: http://t.co/EkimyQQSZW
posted
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Biocartis announces that its researchers, in collaboration with researchers at the Wellcome Trust Sanger Institute and at Philips Research, are developing a novel workflow for extraction and amplification & detection of tumor DNA on Biocartis diagnostic platforms. Biocartis retains its full IP rights, with access to IP created during the scope of this collaboration.
The availability of this test is expected to have a major impact on personalizing treatment of tumors, increasing the quality of clinical care and the quality of life for the patient. Individual decisions on treatment duration and intensity will be in reach and ultimately, this could allow drugs to be targeted to only those patients who show meaningful response, reducing unnecessary side-effects and improving effectiveness.
Cancer is caused by the accumulation of genetic damage (mutations) in cells within a particular organ. These mutations are only found in the cancerous cells, and therefore could be used to monitor the tumor load during treatment, and rapidly evaluate treatment response.
Dr Patrick van den Bogaard, Director of Life Science Research at Biocartis SA comments: “The system will use disposable, microfluidic cartridges with digitally encoded micro particles for the rapid and sensitive detection of multiple DNA samples. The test aims to be highly specific and sensitive, being able to isolate and detect just a few molecules of tumor DNA per ml of blood. To implement such tests in a real-world healthcare system requires development of fully automated, high multiplexing diagnostic instruments and technology which is the core focus of Biocartis.”
Biocartis aims to improve healthcare outcomes by enabling the practice of personalized medicine anywhere, anytime. Biocartis’ ambition is to establish a new gold standard in diagnostic testing.
Biocartis is currently developing innovative diagnostic systems with following key features: fully automated, simultaneous detection of many biomarkers, fast, simplified workflow and minimal hands on time, integrated sample preparation for a broad range of sample types.
Biocartis develops assays which have high clinical utility and compelling health economic value. Oncology is the primary focus of Biocartis as this is one of the greatest unmet needs for personalized medicine. Biocartis’ broad platform capabilities are well suited to address the growing need for individualized diagnosis and treatment of cancer patients.
Biocartis follows a unique alliance model which leverages the combined resources of its current alliance partners (bioMérieux and Janssen Diagnostics) and future alliance members to jointly and efficiently install and service a global base of instruments and develop a broad menu of diagnostic tests.
Biocartis is a rapidly growing company; to date Biocartis staff includes over 120 people. The company has raised in total EUR 125 million in equity.
DMAT (Dynamic Multi-Analyte Technology) is the codename of Biocartis’ Multiplex Assay Platform which enables accelerated development of multi-analyte assays, reduces time-to-result and hands-on time, and provides high quality protein and nucleic acid-based biomarker analysis. Primarily aimed at the life science research market, the platform is perfectly suited for research organizations which need to generate high-quality data faster and with less effort. Its novel architecture streamlines assay development and facilitates rapid adaptation of established panels for specific disease areas.
Biocartis’ digitally encoded micro-particles, which are the core of the platform, allow for the detection of up to 1,000 different analytes in a single sample.
Source: Biocartis
Tags: research
Bookmark this:
